Strategy
MSTR
Meta Platforms
META
Oracle
ORCL
Amazon
AMZN
Salesforce
CRM
US Stock MarketDetailed Quotes
ANIP ANI Pharmaceuticals
- 55.010
- +0.500+0.92%
Close Feb 26 16:00 ET
- 55.010
- 0.0000.00%
Post 16:08 ET
1.16BMarket Cap-117.04P/E (TTM)
55.180High54.100Low273.26KVolume54.640Open54.510Pre Close14.96MTurnover1.70%Turnover Ratio64.72P/E (Static)21.02MShares70.81052wk High2.85P/B883.04MFloat Cap52.50052wk Low--Dividend TTM16.05MShs Float392.040Historical High--Div YieldTTM1.98%Amplitude4.800Historical Low54.737Avg Price1Lot Size
About ANI Pharmaceuticals Company
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
Company Profile
SymbolANIP
Company NameANI Pharmaceuticals
Listing DateOct 1, 2003
Founded1996
CEOMr. Nikhil Lalwani
MarketNASDAQ
Employees642
Fiscal Year Ends12-31
Address210 Main Street West
CityBaudette
ProvinceMinnesota
CountryUnited States of America
Zip Code56623
Phone1-218-634-3500
Company Executives
- Name
- Position
- Salary
- Nikhil Lalwani
- Director, President and Chief Executive Officer
- 8.08M
- Krista Davis
- Senior Vice President and Chief Human Resources Officer
- --
- Stephen P. Carey
- Senior Vice President, Finance, Principal Accounting Officer and Chief Financial Officer
- 2.58M
- James G. Marken
- Senior Vice President, Operations and Product Development
- --
- Chad Gassert
- Senior Vice President, Corporate Development and Strategy
- 1.90M
- Meredith W. Cook
- Senior Vice President, General Counsel and Corporate Secretary
- --
- Ori Gutwerg
- Senior Vice President, Generics
- 1.94M
- Christopher Mutz
- Senior Vice President and Head of Rare Diseases
- 1.91M
- Thomas Rowland
- Senior Vice President, Corporate Development & Strategy
- --
- Patrick D. Walsh
- Chairman of the Board
- 422.21K
- Matthew J. Leonard
- Director
- 928.31K
- Muthusamy Shanmugam
- Director, Head of Research and Development and Chief Operating Office, Novitium Operations
- --
- Thomas J. Haughey
- Independent Director
- 412.21K
- Antonio R. Pera
- Independent Director
- 393.25K
- Dr. Renee P. Tannenbaum, D.Pharm.
- Independent Director
- 392.37K
- Jeanne Thomas
- Independent Director
- 395.75K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.